SMMT - Summit Therapeutics Inc. Latest News | Finranks

12.08.2026

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi.

07.08.2026

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

06.08.2026

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W.

05.08.2026

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus the antibody-drug co.

04.08.2026

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying auto retailer Carvana Co. (NYSE:CVNA) on the heels of its “good” quarter.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
SMMT	Leerink Partners	Market Perform	undefined >> $13	August 12th 2026

Press releases

12.08.2026

Summit Therapeutics Inc. (SMMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Summit Therapeutics Inc. (SMMT)

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

Videos

No Data

Upgrades / Downgrades

Press releases

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Search stocks

Summit Therapeutics Inc. (SMMT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Summit Therapeutics Inc. (SMMT)

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

Videos

No Data

Upgrades / Downgrades

Press releases

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer